Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus

Brain

Volumn 132, Issue 11, 2009, Pages 3134-3141

  Sixt, Marie Luise ^a   Messlinger, Karl ^a   Fischer, Michael J M ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BIBN4096BS; Headache; Migraine; MK 0974

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CAPSAICIN; ISOFLURANE; MITOGEN ACTIVATED PROTEIN KINASE; OLCEGEPANT; PROTEIN FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; MALE; NERVE CELL STIMULATION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RAT; RECEPTOR BLOCKING; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION;

ANIMALS; BIOLOGICAL MARKERS; CALCITONIN GENE-RELATED PEPTIDE; CAPSAICIN; DIPEPTIDES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MIGRAINE DISORDERS; NEURONS; PAIN; PROTO-ONCOGENE PROTEINS C-FOS; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TRIGEMINAL NUCLEUS, SPINAL;

EID: 70350689543     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp168     Document Type: Article

References (47)

1. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999; 398: 43641.
2. Dai Y, Iwata K, Fukuoka T, Kondo E, Tokunaga A, Yamanaka H, et al. Phosphorylation of extracellular signal-regulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. J.Neurosci 2002; 22: 773745.
3. DaSilva AF, Becerra L, Makris N, Strassman AM, Gonzalez RG, Geatrakis N, et al. Somatotopic activation in the human trigeminal pain pathway. J Neurosci 2002; 22: 818392.
4. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 1837.
5. Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, et al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquin azolin-3(4H)-yl)-N-(3-(7- methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piper idin-1-yl)piperidin-1-yl)propan-2-yl) piperidine-1-carboxami de (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008; 51: 485861.
6. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007; 28: 5807.
7. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129: 4203.
8. Durham PL. CGRP-receptor antagonists-a fresh approach to migraine therapy? N Engl J Med 2004; 350: 10735.
9. Durham PL. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache 2008; 48: 126975.
10. Durham PL, Russo AF. Serotonergic repression of mitogen-activated protein kinase control of the calcitonin gene-related peptide enhancer. Mol Endocrinol 1998; 12: 10029.
11. Durham PL, Russo AF. Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci 2003; 23: 80715.
12. Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 2008; 155: 9679.
13. Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 2002; 434: 4953.
14. Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman R. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 1987a; 7: 7208.
15. Edvinsson L, Ekman R, Jansen I, Ottosson A, Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochem-istry, radioimmunoassay, and in vitro pharmacology. Ann Neurol 1987b; 21: 4317.
16. Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 2007; 150: 63340.
17. Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005; 25: 587783.
18. Geppetti P, Del Bianco E, Santicioli P, Lippe IT, Maggi CA, Sicuteri F. Release of sensory neuropeptides from dural venous sinuses of guinea pig. Brain Res 1990; 510: 5862.
19. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 4856.
20. Hershey JC, Corcoran HA, Baskin EP, Salvatore CA, Mosser S, Williams TM, et al. Investigation of the species selectivity of a non-peptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 2005; 127: 717.
21. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008a; 372: 211523.
22. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008b; 70: 130412.
23. Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, toler-ability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004; 24: 64556.
24. Issekutz B Jr, Lichtneckert I, Nagy H. Effect of capsaicin and histamine on heat regulation. Arch Int Pharmacodyn Ther 1950; 81: 3546.
25. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ. Regulation of calci-tonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004; 366: 2414.
26. Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol 1991; 309: 51534.
27. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 5461.
28. Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008; 507: 127799.
29. Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005; 58: 698705.
30. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008; 9: 512.
31. Messlinger K, Hanesch U, Baumgartel M, Trost B, Schmidt RF. Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immuno-reactivity. Anat Embryol 1993; 188: 21937.
32. Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can J Physiol Pharmacol 1995; 73: 10204.
33. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006; 31: 26875.
34. Noma N, Tsuboi Y, Kondo M, Matsumoto M, Sessle BJ, Kitagawa J, et al. Organization of pERK-immunoreactive cells in trigeminal spinal nucleus caudalis and upper cervical cord following capsaicin injection into oral and craniofacial regions in rats. J Comp Neurol 2008; 507: 142840.
35. Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh-Hofer S, Rohde W, et al. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 2005; 25: 22536.
36. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 110410.
37. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004; 143: 697704.
38. Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist 2005; 11: 37386.
39. Price TJ, Patwardhan AM, Flores CM, Hargreaves KM. A role for the anandamide membrane transporter in TRPV1-mediated neuro-secretion from trigeminal sensory neurons. Neuropharmacology 2005; 49: 2539.
40. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 32044.
41. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3- difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2, 3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxa mide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008; 324: 41621.
42. Samsam M, Covenas R, Ahangari R, Yajeya J, Narvaez JA, Tramu G. Alterations in neurokinin A-, substance P-and calcitonin gene-related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the trigeminal ganglion. Neurosci Lett 1999; 261: 17982.
43. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004; 142: 117181.
44. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 1997; 17: 51824.
45. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 6975.
46. Zhuang ZY, Xu H, Clapham DE, Ji RR. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 2004; 24: 83009.
47. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10.